CN104736167B - 含有mhc i型启动子的慢病毒载体 - Google Patents

含有mhc i型启动子的慢病毒载体 Download PDF

Info

Publication number
CN104736167B
CN104736167B CN201380026705.4A CN201380026705A CN104736167B CN 104736167 B CN104736167 B CN 104736167B CN 201380026705 A CN201380026705 A CN 201380026705A CN 104736167 B CN104736167 B CN 104736167B
Authority
CN
China
Prior art keywords
promoter
slow virus
promoters
virus carrier
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380026705.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN104736167A (zh
Inventor
E·萨莉
C·伯奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theravectys SA
Original Assignee
Theravectys SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravectys SA filed Critical Theravectys SA
Publication of CN104736167A publication Critical patent/CN104736167A/zh
Application granted granted Critical
Publication of CN104736167B publication Critical patent/CN104736167B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201380026705.4A 2012-05-23 2013-04-30 含有mhc i型启动子的慢病毒载体 Active CN104736167B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305566.7A EP2666477A1 (en) 2012-05-23 2012-05-23 Lentiviral vectors containing an MHC class I promoter
EP12305566.7 2012-05-23
PCT/EP2013/059041 WO2013174630A1 (en) 2012-05-23 2013-04-30 Lentiviral vectors containing an mhc class i promoter

Publications (2)

Publication Number Publication Date
CN104736167A CN104736167A (zh) 2015-06-24
CN104736167B true CN104736167B (zh) 2018-07-27

Family

ID=48289150

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380026705.4A Active CN104736167B (zh) 2012-05-23 2013-04-30 含有mhc i型启动子的慢病毒载体

Country Status (17)

Country Link
US (1) US8951535B2 (enExample)
EP (2) EP2666477A1 (enExample)
JP (1) JP5938143B2 (enExample)
KR (1) KR101774929B1 (enExample)
CN (1) CN104736167B (enExample)
AU (1) AU2013265586B2 (enExample)
BR (1) BR112014028944B1 (enExample)
CA (1) CA2873473C (enExample)
ES (1) ES2498277T3 (enExample)
IL (1) IL235705A (enExample)
IN (1) IN2014DN10123A (enExample)
NZ (1) NZ702345A (enExample)
PL (1) PL2678032T3 (enExample)
PT (1) PT2678032E (enExample)
SG (1) SG11201407732SA (enExample)
WO (1) WO2013174630A1 (enExample)
ZA (1) ZA201408652B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014195159A1 (en) 2013-06-03 2014-12-11 Theravectys Lentiviral vectors containing an mhc class i, mhc class ii, or beta-2 microglobulin upstream promoter sequence
EP3276006A1 (en) * 2016-07-27 2018-01-31 Theravectys Lentiviral vectors for expression of hepatitis b virus (hbv) antigens
KR102932097B1 (ko) 2020-07-06 2026-02-27 주식회사 지씨셀 면역원성이 감소된 신규한 이식용 세포
CN114107393A (zh) 2021-04-07 2022-03-01 上海劲威生物科技有限公司 一种治疗乙型肝炎的慢病毒载体、慢病毒颗粒及其制备方法和应用
KR102913951B1 (ko) * 2022-11-10 2026-01-20 전남대학교 산학협력단 다중에피토프 펩타이드를 포함하는 신경교종 예방 또는 치료용 약제학적 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19720152A1 (de) * 1997-05-02 1998-11-05 Max Delbrueck Centrum Retrovirales Vektorsystem zur Optimierung des Gentransfers und der Genexpression in primären humanen T-Lymphozyten

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
ES2337429T3 (es) 1999-10-11 2010-04-23 Institut Pasteur Vectores lentivirales para la preparacion de composiciones inmunoterapeuticas.
HK1050210B (en) 1999-10-12 2007-08-24 Institut Pasteur Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US8222029B2 (en) 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
ES2708856T3 (es) 2007-08-03 2019-04-11 Pasteur Institut Vectores de transferencia de gen lentivírico y sus aplicaciones medicinales

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19720152A1 (de) * 1997-05-02 1998-11-05 Max Delbrueck Centrum Retrovirales Vektorsystem zur Optimierung des Gentransfers und der Genexpression in primären humanen T-Lymphozyten

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Adenovirus Type 12 ElA Down Regulates Expression of a Transgene under Control of a Major Histocompatibility Complex Class I Promoter: Evidence for Transcriptional Control;INGEBORG MEIJER等;《JOURNAL OF VIROLOGY》;19890930;第63卷(第9期);第4039-4042页 *
Establishment and Characterization of Conditionally Immortalized Stromal Cell Lines from a Temperature-Sensitive T-Ag Transgenic Mouse;DOMINIK FEUERBACH等;《JOURNAL OF BONE AND MINERAL RESEARCH》;19971231;第12卷(第2期);正文第180页第20-28行， *
Human papillomavirus type 16 (HPV 16) E7 and major histocompatibility complex (MHC) class I and II expression in human keratinocytes in culture;A. Hoos等;《Arch Virol》;19961231;第141卷;第449-458页 *
Interferons Increase Transcription of a Major Histocompatibility Class I Gene via a 5" Interferon Consensus Sequence;KENJI SUGITA等;《MOLECULAR AND CELLULAR BIOLOGY》;19870731;第7卷(第7期);第2626-2630页 *
Lentiviral vectors for cancer immunotherapy:transforming infectious particles into therapeutics;K Breckpot等;《Gene Therapy》;20070322;第14卷;摘要 *
Negative regulation of the major histocompatibility complex class I promoter in embryonal carcinoma cells;JAMES R. FLANAGAN等;《Developmental Biology》;19910430;第88卷;第3145-3149页 *

Also Published As

Publication number Publication date
JP2015518716A (ja) 2015-07-06
CA2873473C (en) 2019-05-07
CN104736167A (zh) 2015-06-24
BR112014028944B1 (pt) 2020-11-10
KR20150014472A (ko) 2015-02-06
EP2666477A1 (en) 2013-11-27
HK1211837A1 (en) 2016-06-03
JP5938143B2 (ja) 2016-06-22
US20140120132A1 (en) 2014-05-01
EP2678032B1 (en) 2014-06-18
AU2013265586B2 (en) 2015-09-03
IN2014DN10123A (enExample) 2015-08-21
PT2678032E (pt) 2014-09-09
WO2013174630A1 (en) 2013-11-28
EP2678032A1 (en) 2014-01-01
IL235705A0 (en) 2015-01-29
AU2013265586A1 (en) 2014-12-11
IL235705A (en) 2016-10-31
US8951535B2 (en) 2015-02-10
PL2678032T3 (pl) 2014-11-28
NZ702345A (en) 2016-03-31
BR112014028944A2 (pt) 2015-09-29
CA2873473A1 (en) 2013-11-28
KR101774929B1 (ko) 2017-09-19
ES2498277T3 (es) 2014-09-24
SG11201407732SA (en) 2014-12-30
ZA201408652B (en) 2016-09-28

Similar Documents

Publication Publication Date Title
CN105683383B (zh) 含有I型MHC、II型MHC或β2微球蛋白上游启动子序列的慢病毒载体
JP5265643B2 (ja) 免疫治療組成物調製用のレンチウイルスベクター
US20230364216A1 (en) Lentiviral vectors enabling routing antigens to mhc-ii pathway and inducing cd4+ and cd8+ t-cell responses in a host
JP5938143B2 (ja) Ｍｈｃクラスｉプロモーターを含有するレンチウイルスベクター
JP6612237B2 (ja) ヒトｔリンパ向性ウイルス１型に対する免疫応答を生成するためのレンチウイルスベクター
US20110236418A1 (en) Materials and Methods for Improved Vaccination
CN109923212B (zh) 用于表达乙肝病毒（hbv）抗原的慢病毒载体
HK1211837B (en) Lentiviral vectors containing an mhc class i promoter

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1211837

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant